ACTH protects against glucocorticoid-induced osteonecrosis of bone
Proceedings of the National Academy of Sciences, 2010•National Acad Sciences
We report that adrenocorticotropic hormone (ACTH) protects against osteonecrosis of the
femoral head induced by depot methylprednisolone acetate (depomedrol). This therapeutic
response likely arises from enhanced osteoblastic support and the stimulation of VEGF by
ACTH; the latter is largely responsible for maintaining the fine vascular network that
surrounds highly remodeling bone. We suggest examining the efficacy of ACTH in
preventing human osteonecrosis, a devastating complication of glucocorticoid therapy.
femoral head induced by depot methylprednisolone acetate (depomedrol). This therapeutic
response likely arises from enhanced osteoblastic support and the stimulation of VEGF by
ACTH; the latter is largely responsible for maintaining the fine vascular network that
surrounds highly remodeling bone. We suggest examining the efficacy of ACTH in
preventing human osteonecrosis, a devastating complication of glucocorticoid therapy.
We report that adrenocorticotropic hormone (ACTH) protects against osteonecrosis of the femoral head induced by depot methylprednisolone acetate (depomedrol). This therapeutic response likely arises from enhanced osteoblastic support and the stimulation of VEGF by ACTH; the latter is largely responsible for maintaining the fine vascular network that surrounds highly remodeling bone. We suggest examining the efficacy of ACTH in preventing human osteonecrosis, a devastating complication of glucocorticoid therapy.
National Acad Sciences